The augmented neutrophil respiratory burst in response to Escherichia coli is reduced in liver cirrhosis during infection

Clinical and Experimental Immunology

Volumn 164, Issue 3, 2011, Pages 346-356

  Bruns, T ^a,b   Peter, J ^a   Hagel, S ^a,b   Herrmann, A ^a   Stallmach, A ^a,b  

^a JENA UNIVERSITY HOSPITAL   (Germany)

^b Center for Sepsis Control and Care (CSCC)   (Germany)

Author keywords

Cirrhosis; Endotoxaemia; Infection; Neutrophil function; Respiratory burst oxidative state

Indexed keywords

AUTOANTIBODY; BIOLOGICAL MARKER; C REACTIVE PROTEIN; IMMUNOGLOBULIN G ANTIBODY; LIPOPOLYSACCHARIDE BINDING PROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN; REACTIVE OXYGEN METABOLITE;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; ESCHERICHIA COLI; FEMALE; HUMAN; HUMAN CELL; INFECTION; INFECTION RISK; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MONOCYTE; NEUTROPHIL; NONHUMAN; OXIDATIVE STRESS; PHAGOCYTE; PRIORITY JOURNAL; RESPIRATORY BURST; SEPSIS;

ACUTE-PHASE PROTEINS; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, BACTERIAL; CARRIER PROTEINS; CELLS, CULTURED; DISEASE PROGRESSION; ESCHERICHIA COLI; FEMALE; FIBROSIS; HUMANS; INFECTION; LIVER; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; NEUTROPHILS; REACTIVE OXYGEN SPECIES; RESPIRATORY BURST;

EID: 79955408892     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2011.04373.x     Document Type: Article

References (55)

1. Borzio M, Salerno F, Piantoni L etal. Bacterial infection in patients with advanced cirrhosis: a multicentre prospective study. Dig Liver Dis 2001; 33:41-8.
2. Foreman MG, Mannino DM, Moss M. Cirrhosis as a risk factor for sepsis and death: analysis of the National Hospital Discharge Survey. Chest 2003; 124:1016-20.
3. Arvaniti V, D'Amico G, Fede G etal. Infections in patients with cirrhosis increase mortality 4-fold and should be used in determining prognosis. Gastroenterology 2010; 139:1246-56.
4. Guerra-Ruiz A, Casafont F, Cobo M etal. Increased bactericidal/permeability increasing protein in patients with cirrhosis. Liver Int 2010; 30:94-101.
5. Babior BM. Phagocytes and oxidative stress. Am J Med 2000; 109:33-44.
6. Guthrie LA, McPhail LC, Henson PM, Johnston RB. Priming of neutrophils for enhanced release of oxygen metabolites by bacterial lipopolysaccharide. Evidence for increased activity of the superoxide-producing enzyme. J Exp Med 1984; 160:1656-71.
7. Sheppard FR, Kelher MR, Moore EE, McLaughlin NJD, Banerjee A, Silliman CC. Structural organization of the neutrophil NADPH oxidase: phosphorylation and translocation during priming and activation. J Leukoc Biol 2005; 78:1025-42.
8. Cowburn AS, Condliffe AM, Farahi N, Summers C, Chilvers ER. Advances in neutrophil biology: clinical implications. Chest 2008; 134:606-12.
9. Speer CP, Pabst MJ, Hedegaard HB, Rest RF, Johnston RB. Enhanced release of oxygen metabolites by monocyte-derived macrophages exposed to proteolytic enzymes: activity of neutrophil elastase and cathepsin G. J Immunol 1984; 133:2151-6.
10. Soehnlein O, Kenne E, Rotzius P, Eriksson EE, Lindbom L. Neutrophil secretion products regulate anti-bacterial activity in monocytes and macrophages. Clin Exp Immunol 2008; 151:139-45.
11. Zhao X, Carnevale KA, Cathcart MK. Human monocytes use Rac1, not Rac2, in the NADPH oxidase complex. J Biol Chem 2003; 278:40788-92.
12. Pabst M, Pabst K, Handsman D, Beranova-Giorgianni S, Giorgianni F. Proteome of monocyte priming by lipopolysaccharide, including changes in interleukin-1beta and leukocyte elastase inhibitor. Proteome Sci 2008; 6:13. Available at
13. van Leeuwen HJ, van der Tol M, van Strijp JAG, Verhoef J, van Kessel KPM. The role of tumour necrosis factor in the kinetics of lipopolysaccharide-mediated neutrophil priming in whole blood. Clin Exp Immunol 2005; 140:65-72.
14. Wiest R, Garcia-Tsao G. Bacterial translocation (BT) in cirrhosis. Hepatology 2005; 41:422-33.
15. Zapater P, Francés R, González-Navajas JM etal. Serum and ascitic fluid bacterial DNA: a new independent prognostic factor in noninfected patients with cirrhosis. Hepatology 2008; 48:1924-31.
16. Bruns T, Sachse S, Straube E etal. Identification of bacterial DNA in neutrocytic and non-neutrocytic cirrhotic ascites by means of a multiplex polymerase chain reaction. Liver Int 2009; 29:1206-14.
17. Lin C, Tsai I, Ho Y etal. Endotoxaemia contributes to the immune paralysis in patients with cirrhosis. J Hepatol 2007; 46:816-26.
18. Albillos A, de la Hera A, González M etal. Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement. Hepatology 2003; 37:208-17.
19. Albillos A, de-la-Hera A, Alvarez-Mon M. Serum lipopolysaccharide-binding protein prediction of severe bacterial infection in cirrhotic patients with ascites. Lancet 2004; 363:1608-10.
20. Gomez F, Ruiz P, Schreiber AD. Impaired function of macrophage Fc gamma receptors and bacterial infection in alcoholic cirrhosis. N Engl J Med 1994; 331:1122-8.
21. Fiuza C, Salcedo M, Clemente G, Tellado JM. Granulocyte colony-stimulating factor improves deficient in vitro neutrophil transendothelial migration in patients with advanced liver disease. Clin Diagn Lab Immunol 2002; 9:433-9.
22. Rajkovic IA, Williams R. Mechanisms of abnormalities in host defences against bacterial infection in liver disease. Clin Sci 1985; 68:247-53.
23. Fiuza C, Salcedo M, Clemente G, Tellado JM. In vivo neutrophil dysfunction in cirrhotic patients with advanced liver disease. J Infect Dis 2000; 182:526-33.
24. Stanley AJ, MacGregor IR, Dillon JF, Bouchier IA, Hayes PC. Neutrophil activation in chronic liver disease. Eur J Gastroenterol Hepatol 1996; 8:135-8.
25. Masini E, Mugnai L, Foschi M, Laffi G, Gentilini P, Mannaioni PF. Changes in the production of nitric oxide and superoxide by inflammatory cells in liver cirrhosis. Int Arch Allergy Immunol 1995; 107:197-8.
26. Taïeb J, Mathurin P, Elbim C etal. Blood neutrophil functions and cytokine release in severe alcoholic hepatitis: effect of corticosteroids. J Hepatol 2000; 32:579-86.
27. Mookerjee RP, Stadlbauer V, Lidder S etal. Neutrophil dysfunction in alcoholic hepatitis superimposed on cirrhosis is reversible and predicts the outcome. Hepatology 2007; 46:831-40.
28. Panasiuk A, Wysocka J, Maciorkowska E etal. Phagocytic and oxidative burst activity of neutrophils in the end stage of liver cirrhosis. World J Gastroenterol 2005; 11:7661-5.
29. Fung YL, Fraser JF, Wood P, Minchinton RM, Silliman CC. The systemic inflammatory response syndrome induces functional changes and relative hyporesponsiveness in neutrophils. J Crit Care 2008; 23:542-9.
30. Wenisch C, Parschalk B, Patruta S, Brustbauer R, Graninger W. Effect of polyclonal immunoglobulins on neutrophil phagocytic capacity and reactive oxygen production in patients with Gram-negative septicaemia. Infection 1999; 27:183-6.
31. Schumann RR, Leong SR, Flaggs GW etal. Structure and function of lipopolysaccharide binding protein. Science 1990; 249:1429-31.
32. Maggi E, Marchesi E, Ravetta V, Martignoni A, Finardi G, Bellomo G. Presence of autoantibodies against oxidatively modified low-density lipoprotein in essential hypertension: a biochemical signature of an enhanced in vivo low-density lipoprotein oxidation. J Hypertens 1995; 13:129-38.
33. Shoenfeld Y, Wu R, Dearing LD, Matsuura E. Are anti-oxidized low-density lipoprotein antibodies pathogenic or protective? Circulation 2004; 110:2552-8.
34. Seder RA, Darrah PA, Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol 2008; 8:247-58.
35. Czermak BJ, Sarma V, Pierson CL etal. Protective effects of C5a blockade in sepsis. Nat Med 1999; 5:788-92.
36. Reddy RC, Chen GH, Tekchandani PK, Standiford TJ. Sepsis-induced immunosuppression: from bad to worse. Immunol Res 2001; 24:273-87.
37. Kaufmann I, Hoelzl A, Schliephake F etal. Polymorphonuclear leukocyte dysfunction syndrome in patients with increasing sepsis severity. Shock 2006; 26:254-61.
38. Yekebas EF, Eisenberger CF, Ohnesorge H etal. Attenuation of sepsis-related immunoparalysis by continuous veno-venous hemofiltration in experimental porcine pancreatitis. Crit Care Med 2001; 29:1423-30.
39. Tennenberg SD, Solomkin JS. Neutrophil activation in sepsis. The relationship between fmet-leu-phe receptor mobilization and oxidative activity. Arch Surg 1988; 123:171-5.
40. Tschaikowsky K, Sittl R, Braun GG, Hering W, Rügheimer E. Increased fMet-Leu-Phe receptor expression and altered superoxide production of neutrophil granulocytes in septic and posttraumatic patients. Clin Invest 1993; 72:18-25.
41. Shawcross DL, Wright GAK, Stadlbauer V etal. Ammonia impairs neutrophil phagocytic function in liver disease. Hepatology 2008; 48:1202-12.
42. Sibelius U, Hattar K, Hoffmann S etal. Distinct pathways of lipopolysaccharide priming of human neutrophil respiratory burst: role of lipid mediator synthesis and sensitivity to interleukin-10. Crit Care Med 2002; 30:2306-12.
43. Yan SR, Al-Hertani W, Byers D, Bortolussi R. Lipopolysaccharide-binding protein- and CD14-dependent activation of mitogen-activated protein kinase p38 by lipopolysaccharide in human neutrophils is associated with priming of respiratory burst. Infect Immun 2002; 70:4068-74.
44. Hailman E, Vasselon T, Kelley M etal. Stimulation of macrophages and neutrophils by complexes of lipopolysaccharide and soluble CD14. J Immunol 1996; 156:4384-90.
45. Lamping N, Dettmer R, Schröder NW etal. LPS-binding protein protects mice from septic shock caused by LPS or Gram-negative bacteria. J Clin Invest 1998; 101:2065-71.
46. Zweigner J, Gramm HJ, Singer OC, Wegscheider K, Schumann RR. High concentrations of lipopolysaccharide-binding protein in serum of patients with severe sepsis or septic shock inhibit the lipopolysaccharide response in human monocytes. Blood 2001; 98:3800-8.
47. Opal SM, Scannon PJ, Vincent JL etal. Relationship between plasma levels of lipopolysaccharide (LPS) and LPS-binding protein in patients with severe sepsis and septic shock. J Infect Dis 1999; 180:1584-9.
48. Vesy CJ, Kitchens RL, Wolfbauer G, Albers JJ, Munford RS. Lipopolysaccharide-binding protein and phospholipid transfer protein release lipopolysaccharides from Gram-negative bacterial membranes. Infect Immun 2000; 68:2410-17.
49. Thompson PA, Tobias PS, Viriyakosol S, Kirkland TN, Kitchens RL. Lipopolysaccharide (LPS)-binding protein inhibits responses to cell-bound LPS. J Biol Chem 2003; 278:28367-71.
50. Cathcart MK, Morel DW, Chisolm GM. Monocytes and neutrophils oxidize low density lipoprotein making it cytotoxic. J Leukoc Biol 1985; 38:341-50.
51. Schneiderhan W, Schmid-Kotsas A, Zhao J etal. Oxidized low-density lipoproteins bind to the scavenger receptor, CD36, of hepatic stellate cells and stimulate extracellular matrix synthesis. Hepatology 2001; 34:729-37.
52. Wiesner P, Choi S, Almazan F etal. Low doses of lipopolysaccharide and minimally oxidized low-density lipoprotein cooperatively activate macrophages via nuclear factor kappab and activator protein-1: possible mechanism for acceleration of atherosclerosis by subclinical endotoxaemia. Circ Res 2010; 107:56-65.
53. Geng H, Wang A, Rong G etal. The effects of ox-LDL in human atherosclerosis may be mediated in part via the toll-like receptor 4 pathway. Mol Cell Biochem 2010; 342:201-6.
54. Lopes-Virella MF. Interactions between bacterial lipopolysaccharides and serum lipoproteins and their possible role in coronary heart disease. Eur Heart J 1993; 14:118-24.
55. Charach G, George J, Afek A etal. Antibodies to oxidized LDL as predictors of morbidity and mortality in patients with chronic heart failure. J Card Fail 2009; 15:770-4.